New drug mechanisms for SpA. Nice to have expanding options #ACR20 https://t.co/vlTwaiuuS3

4.CIRT: low dose MTX 15 mg/week: transaminitis NNH 6, cirrhosis NNH 1000 5.LoDoCo2: colchicine prevents MACE: NNT 36 6.ENTRACTE: TCZ vs ETN: for bowel perforation TCZ: NNH 600

Year in Review by @JYazdanyMD: #Cardiovascular #Inflammation Reduction Trial provided "unique opportunity to learn about side-effects" of a drug we commonly use. Low-dose MTX assoc. with small-mod. elevated risk of transaminitis, infection, anaemia & skin cancer. #ACR20 @RheumNow https://t.co/hNS600Pndr

How do you monitor HCQ on patients with chronic QTc prolonging medications (ex psychiatric meds)? @JYazdanyMD Year-in-Review #ACR20 @rheumnow

Do you plan to do a skin exam in your RA patients on MTX given new toxicity signal of skin cancer based on CIRT with NNH of 167? @JYazdanyMD #ACR20 Year in Review @RheumNow

Dr Kevin Wei's study with @ilyakorsunsky @Deepakarao @soumya_boston, Dr. Michael Brenner and others at @BrighamResearch featured in the basic year-in-review at #ACR20 showing Notch signaling importance in synovium from arthritis #ACRambassador

What is most important clinical study in last year? #ACR20 @rheumnow

Mavrilimumab (anti GM-CSF Receptor α Monoclonal Antibody) Reduces Time to Flare and Increases Sustained Remission in a Phase 2 Trial of Patients with Giant Cell Arteritis https://t.co/1kqWeBcEDq #gca #GmCSFinh Novel MOA , big unmet need

• Mavrilimumab (anti GM-CSF Receptor α Monoclonal Antibody) Reduces Time to Flare…

Efficacy & Safety Deucravacitinib (BMS-986165), Oral, Selective TyK2 Inhib in Patients with Active PsA Results from a Phase 2, RDBPC Trial https://t.co/s3V5NtRpuW results-from-a-phase-2-randomized-double-blind-plac/ #psa #tyk2inhib Efficacy in PsA ?top of dose response

• https://acrabstracts.org/abstract/efficacy-and-safety-of-deucravacitinib-bms-98…

Long Term Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Chronic Gout: The Febuxostat versus Allopurinol Streamlined Trial (on Behalf of the FAST Investigators) https://t.co/LGERY3mpe5 #febuxostat #allopurinol #CVS some cardiac reassurance feboxustat

• Long Term Cardiovascular Safety of Febuxostat and Allopurinol in Patients with …

Tofacitinib for the Treatment of Adult Patients with Ankylosing Spondylitis: Primary Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study https://t.co/F86K1Lqou7 #tofacitinib #AS Tofa works in AS , zoster no VTE seen NNH 20(per SAE) NNT 2.5(per ASAS40)

• Tofacitinib for the Treatment of Adult Patients with Ankylosing Spondylitis: Pr…

The #ACR20 Great Debate will feature two experts discussing whether #JAK inhibitors should be used before biologics if methotrexate fails. The session runs Friday, Nov. 6., from 10:00 to 11:00 AM ET. Learn more → https://t.co/I8zTGn0Q06

• Great Debate to consider starting JAK inhibitors sooner - ACR Convergence Today

Our daily update is published. States reported record numbers of tests (1.5 million) and cases (116k). Hospitalizations continue their sharp rise. The death toll was 1,124. https://t.co/z3gxwP6EaC

Dr. Dinesh Khanna (@sclerodermaUM): In post-hoc analysis of focuSSed trial of tocilizumab vs. placebo, disease duration, male gender, elevated acute phase reactants, and anti-SCL-70 Ab have a larger beneficial effect on FVC in early SSc-ILD. #ATS2020 #MiniSymposia @UMIntMed 10/

One of the many HOT sessions tomorrow #ACR20 I am planning on - IFN is center stage in autoinflammatory/autoimmune/infectious diseases especially-hope they cover IFN autoantibodies!! #COVID19 - @CCalabreseDO @JYazdanyMD @canallab @MaxKonigMD @AdamJBrownMD @TiphaineLft https://t.co/uDauMkGsjX